Active Focal Segmental Glomerulosclerosis Is Associated with Massive Oxidation of Plasma Albumin
Luca Musante*,,
Giovanni Candiano*,
Andrea Petretto,
Maurizio Bruschi*,,
Nazzareno Dimasi,
Gianluca Caridi*,
Barbara Pavone||,¶,**,
Piero Del Boccio||,¶,**,
Monica Galliano,
Andrea Urbani||,¶,**,
Francesco Scolari,
Flavio Vincenti and
Gian Marco Ghiggeri*
* Laboratory on Pathophysiology of Uremia, Mass Spectrometry Core Facility, Laboratory of Molecular Medicine, G. Gaslini Children Hospital, and Renal Child Foundation, Genoa, || Department of Biomedical Science, Università degli Studi di Chieti e Pescara, Chieti, ¶ Centro Studi sullInvecchiamento, Fondazione Università "G. DAnnunzio," Chieti, ** IRCCS-Fondazione Santa Lucia, Rome, Department of Biochemistry, University of Pavia, Pavia, and Department of Nephrology, University of Brescia, Brescia, Italy; and Transplant Service, University of California, San Francisco, San Francisco, California
Address correspondence to: Dr. Gian Marco Ghiggeri, Laboratory on Pathophysiology of Uremia, G. Gaslini Children Hospital, Largo G. Gaslini, 5. 16148 Genova, Italy. Phone: +39-010-380742; Fax: +39-010-395214; E-mail: labnefro{at}ospedale-gaslini.ge.it
Received for publication September 6, 2006.
Accepted for publication December 18, 2006.
The basic mechanism for idiopathic FSGS still is obscure. Indirectevidence in humans and generation of FSGS by oxidants in experimentalmodels suggest a role of free radicals. In vitro studies demonstratea main role of plasma albumin as antioxidant, its modificationrepresenting a chemical marker of oxidative stress. With theuse of complementary liquid chromatography electron spray ionizationtandem mass spectrometry (LC-ESI-MS/MS) and biochemical methods,plasma albumin was characterized in 34 patients with FSGS; 18had received a renal transplant, and 17 had IgM mesangial deposition.Patients with FSGS that was in remission or without recurrenceafter transplantation had normal plasma albumin, and the sameoccurred in patients with primary and secondary nephrites andwith chronic renal failure. In contrast, patients with activeFSGS or with posttransplantation recurrence had oxidized plasmaalbumin. This finding was based on the characterization of albuminCys 34 with an mass-to-charge ratio of 511.71 in triple chargethat was consistent with the formation of a cysteic acid carryinga sulfonic group (alb-SO3). The exact mass of albuminwas increased accordingly (+48 Da) for incorporation of threeoxygen radicals. Direct titration of the free sulfhydryl group34 of plasma albumin and electrophoretic titration curves confirmedloss of free sulfhydryl group and formation of a fast-movingisoform in all cases with disease activity. This is the firstdemonstration of in vivo plasma albumin oxidation that was obtainedwith an adequate structural approach. Albumin oxidation seemsto be specific for FSGS, suggesting some pathogenetic implications.Free radical involvement in FSGS may lead to specific therapeuticinterventions.
FSGS is a degenerative disease of the kidney that is characterizedby focal accumulation of extracellular matrix in glomeruli.It is a heterogeneous condition that includes different variants(14), possible genetic background (5), and variable responseto drugs that modify long-term outcome (6). The basic lesionranges from minimal glomerular involvement to segmental-globalglomerulosclerosis that probably represents an evolutionarystage in patients who are unresponsive to drugs (1,4). On clinicalgrounds, FSGS usually has an abrupt onset with heavy proteinuria,hypoalbuminemia, and frequent progression to renal failure.Notwithstanding some recent advances on the characterizationof genes that are responsible for congenital FSGS (711),little is known of the pathogenesis of the idiopathic form.The disease typically presents clinical recurrences after infectiousepisodes and a remarkable percentage of 30 to 50% of patientswho have FSGS and receive renal allograft have posttransplantationrecurrence (1215). Abnormal T cell responses, have beensuggested to be involved in the pathogenesis of the idiopathicform and in posttransplantation recurrences but remain poorlydefined and lack specificity (16). On the basis of the rapidposttransplantation recurrence, an implication of circulatingplasma factors that persist over time and modify glomerularpermeability to proteins long has been suspected (13,14). Unfortunately,the identification and the characterization of the circulatingfactors have been elusive (17,18), and, more recently, otherpathogenetic mechanisms have been proposed (19).
In an attempt to elucidate the pathogenesis of FSGS, we embarkedon a proteomics approach to study plasma proteins in these patients.Our previous studies in patients with FSGS (20) demonstratedmassive oxidation of plasma albumin, resulting in modificationof the structure of the protein. We proposed that massive oxidationplays a role in the pathogenesis of the proteinuria that isassociated with FSGS. In this study, we devised a mass spectrometrytechnique for analysis of native plasma albumin that is morereproducible and abolished the need for chemical manipulationof the protein. The structural analysis of albumin then wasextended to a wide cohort of patients with nephrotic syndromeand to patients with posttransplantation recurrence of FSGS.Children who had other forms of primary and secondary glomerulonephritisand/or chronic renal failure (end-stage renal failure [ESRF])and were undergoing various treatments also were studied todefine specificity of our structural approach. New methodologicassays also were developed to titrate free sulfhydryl group(SH) of Cys 34 and to determine the occurrence of neutral toacid transition (N-A) in large-scale screening studies.
Chemicals
Acrylamide and ampholine were from Amersham Bioscience (Uppsala,Sweden); N,N'-methylenebisacrylamide, SDS, N,N,N',N'-tetramethylethylenediamine,and electrophoresis calibration standard proteins were fromBio-Rad Laboratories (Hercules, CA). All other chemicals, ofanalytical and electrophoretic grade, were purchased from BDH(Poole, UK). Solutions were prepared fresh using Milli-Q (Millipore,Milan, Italy).
Patients FSGS/IgM.
Thirty-four patients with FSGS, 18 of whom received a renaltransplant and 17 of whom had IgM mesangial proliferative glomerulonephritis,were enrolled in the study (Tables 1 and 2). Twelve patientsof the FSGS group were presenting nephrotic syndrome at thetime of the enrollment; four had been in stable remission inthe previous 2 yr. Eleven patients of the group with mesangialIgM deposits were presenting florid proteinuria and nephroticsyndrome at the time of the study, and the remaining six werein stable remission. The general criteria for enrollment were(1) availability of a clear histology diagnosis on the basisof accepted criteria and (2) absence of familiarity and/or relevantmutations of slit diaphragm genes (NPHS2, CD2AP, and ACTN4).Nephrotic syndrome was defined by the presence of florid proteinuria>40 mg/h per m2. Renal biopsies were processed by standardprocedures for light microscopy, immunofluorescence studies,and electron microscopy. Clinical and pathologic features (e.g.,gender, age at onset of proteinuria, treatment, evolution towardrenal failure, renal transplant) are reported in Tables 1 and2. Patients with FSGS and IgM and with active proteinuria werereceiving treatment with steroids alone (at variable dosages)or in association with cyclosporin and with angiotensin-convertingenzyme inhibitors (ACEi). Steroids were given in a startingdosage of prednisolone 2 mg/kg followed by a gradual taper (21).Cyclosporin was administered at 5 mg/kg starting dosage, followedby dosage adjustment to maintain cyclosporin serum levels between50 and 100 ng/ml (6). Six patients of the stable remission groupswith either FSGS or IgM were still receiving cyclosporin; ACEiwas used in one. Eighteen children with FSGS had developed ESRFand had received a cadaver renal transplant. Immunosuppressiontherapy in these patients included tacrolimus or cyclosporin,mycophenolate mofetil, and steroids. Fourteen patients of thiscohort had posttransplantation recurrence of proteinuria thatwas treated with plasmapheresis (1.5-ml plasma exchange withalbumin as the unique replacement protein) in all but one patientand was associated with cyclophosphamide 2 mg/kg for 2 mo inone patient.
Table 2. Clinical parameters in 18 children who had idiopathic FSGS and developed ESRF and received a renal graft.
ESRF.
Nine patients who had chronic renal failure and were undergoingvarious treatments were enrolled. One was a child (patient 1),two were adolescents (patients 2 and 9), and six were youngadults who developed ESRD for various reasons (Table 3). Thetherapeutic approach was hemodialysis in six cases, and twopatients were maintained on a conservative treatment.
Table 3. Clinical and biochemical parameters in nine patients with chronic renal failure from various renal pathologiesa
Membranous Glomerulonephritis.
Eight patients had received a diagnosis of membranous nephropathyand were all in the proteinuric phase of the disease (Table 4).All but one were adults and were presenting a variable degreeof proteinuria from 1 to 8 g/d. Patients with membranous glomerulonephritis(MGN) were receiving steroids as single drug (1 to 2 mg/kg)or in combination with immune suppressors (22); in some cases,ACEi (ramipril 5 to 8 mg/m2) had been associated.
Table 4. Clinical and biochemical parameters in patients with different primary renal pathologies involving the glomerulusa
Membrane Proliferative Glomerulonephritis.
Four patients had a histology diagnosis of membrane proliferativeglomerulonephritis (MPGN) that presented with proteinuria, hematuria,and normal renal function without arterial hypertension (Table 4).All were receiving prednisolone (1 mg/kg) for at least 2 mo.
IgA.
Five patients had a recent diagnosis of IgA in the absence ofrelevant proteinuria. Only one was treated with steroids; inthree cases, it was used in a scheme with ACEi (Table 4).
Normal Control Subjects.
The control group consisted of 18 healthy adult control subjects.
In all cases plasma was obtained in the morning after an overnightfast. In patients with posttransplantation recurrence, plasmawas obtained at the onset of proteinuria and during the follow-up.Morning fresh urine was collected in sterile condition withoutadditive and frozen at 80°C within 1 h. Plasma wasfrozen within 1 h and was maintained at 80°C undervacuum. Appropriate informed consent was obtained from all patientsin the study.
Purification of Albumin from Healthy Donors and Patients
Albumin was purified from plasma of healthy donors and patientswith FSGS by preparative continuous monodimensional PAGE electrophoresis(total acrylamide concentration = 4 to 12%) in native conditionswith 2-mm gel spacers. All purification steps were performedin a native condition to prevent structural modifications accordingto Margolis and Kenrick (23). One milliliter of serum was appliedto gel, and electrophoresis was run in Tris-borate-EDTA (80/90/2.5mM) for 12 h with 16 mA at 12°C. Albumin was desorbed fromacrylamide by gentle pestle and was maintained in PBS at 4°Cfor 24 h with two changes of the solution.
Liquid Chromatography Electron Spray Ionization Tandem Mass Spectrometry (LC-ESI-MS/MS) for Tryptic Digest Characterization
Albumin after purification was delipidated first in a methanol:acetone:tributylphosphate (1:12:1) with gentle agitation at room temperatureovernight and then was digested by trypsin. Trypsin was addedat an enzyme substrate ratio of 1:30 (wt/wt) in a solution of100 mM ammonium bicarbonate and 1 mM CaCl2 (pH 8.5). After overnightincubation at 37°C, the reaction was stopped with formicacid to pH 2.
All mass spectrometric measurements were performed using anLTQ linear trap mass spectrometer (Thermo Electron, San Jose,CA) coupled to an HPLC Surveyor (Thermo Electron) and equippedwith a Jupiter C18 column 250 x 1 mm (Phenomenex, Torrance,CA). Peptides were eluted from the column using an acetonitrilegradient, 5% B for 6 min followed by 5 to 90% B within 109 min(eluent A: 0.1% formic acid in water; eluent B: 0.1% formicacid in acetonitrile) at a flow rate of 50 µl/min. Thecolumn effluent was directed into the electrospray source. Thespray voltage was 5.0 kV. The capillary of ion trap was keptat 200°C, and the voltage was kept at 2.85 V. Spectra wereacquired in automated MS/MS mode: Each full MS scan (in therange 400 to 1800 mass-to-charge ratio [m/z]) was followed byfive MS/MS of the most abundant ions; mass that had been analyzedmore than two times this way was automatically taken up intoan exclusion list for 30 s. Computer analysis of peptide MS/MSspectra was performed using Bioworks software, version 3.2 (ThermoElectron) and searched against an ALB protein database. PeptideMS/MS assignments were filtered according to the following criteria:cross-correlation (Xcorr) 1.9 for the singly charged ions,Xcorr 2.2 for doubly charged ions, and Xcorr 3.7 for triplycharged ions; peptide probability 0.001; change in correlationvalue (Cn) 0.1; and percentage of ions 30%. For all protein,two missed cleavages was allowed.
ESI-MS for Exact Mass
Albumin-containing solutions were injected manually (5 µl)into an on-line flow, using a CapLC system (Micromass, Waters,Milford, MA) coupled with a nano-ESI-Q-TOF (quadrupoletime-of-flight)instrument (Micromass, Waters). The sample was eluted at 1 µl/minon a C4 precolumn LC-Packings, 300 µm inner diameter x20 mm. Elution was achieved isocratically by H2O/ACN 50/50 bothwith 0.1% TFA and directed into a mass spectrometer equippedwith a nano-Lock-Spray source. A 2500- and 50-V tension wasapplied to the PicoTip capillary (PicoTip Emitter, tip 10 ±1 µm; New Objective, Woburn, MA) and cone voltage, respectively,and the positive ion mode for ion scan experiment was used tomonitor the 700- to 2200-m/z range. Data analysis was performedusing Masslynx version 4.0 (Micromass/Waters). The data collectedwere examined for multiply charged protein spectra, which thenwere integrated to provide a single combined spectrum for theprotein injected. A maximum entropy deconvolution algorithm(MaxEnt1) was used to deconvolute multiply charged spectra andproduce molecular mass spectra.
Electrophoretic Titration Curves
For electrophoretic titration curves, we used total plasma inanticoagulant citrate dextrose. Titration was performed accordingto Bruschi et al. (24). Both methods for electrophoresis runsand calculations have been described previously (24,25).
"In Gel" Determination of Free SH Accessibility
Free SH group titration in plasma albumin was done with themaleimide-PEO2-Biotin (biotinyl-3-maleimidopropionamidyl-3,6-dioxactanediamine)assay (Pierce, Rockford, IL) according to the manufacturersinstructions. After reaction with maleimide- PEO2-Biotin, plasmaproteins first were separated in monodimensional polyacrylamidegels performed according to Laemmli (26) without mercapto-ethanol.After electrophoresis (total acrylamide concentration = 5 to16%; degree of cross-link = 2.67%) reactivity of SH groups withmaleimide was allowed at pH 6.5 for 2 h at 37°C. Streptavidinthat was conjugated with horseradish peroxidase was used todetermine biotin incorporation with 2-(4'-hydroxyazobenzene)-benzoicacid using the EZ Biotin Quantitation Kit (Pierce) at 500 nmwith correction for the amount of albumin as determined by CoomassieR-250. A calibration curve that consisted of four dilutionsof the same serum with known concentration of albumin was usedas standard. Specificity of the maleimide dye for the free SHgroup of Cys 34 was demonstrated by preventing the binding withmethyl-methanethiosulfonate that specifically binds this groupat pH 5.
Albumin Degradation In Vitro
A total of 100 µg of purified albumin was incubated at37°C for 16 h with 0.1 µg/ml (wt/vol) of bovine trypsinin a medium that contained 50 mM Tris-HCl (pH 7.8) and 5 mmCaCl2. The digestion was stopped by addition of Laemmli reducingsample buffer (10 mM Tris-HCl [pH 8.8], 1% [wt/vol] SDS, 1 mMEDTA, 20% [vol/vol] glycerol, and 5% [vol/vol] -mercaptoethanol)(26). After 1 h, the samples were loaded on 8 to 18% (wt/vol)gradient SDS-PAGE and run at 45 mA at 12°C. Gel was fixedwith 40% (vol/vol) ethanol and 10% (vol/vol) acetic acid andstained by silver nitrate.
Albumin Gene DNA Sequence
Genomic DNA was extracted from patient blood. The 14 codingexons of human albumin gene and their intro-exon junctions werePCR-amplified with specific primer pairs as already describedby Watkins et al. (27). Amplicons were purified by Exo-SAP-IT(Amersham Bioscience, Milan, Italy) and directly subjected todirect sequencing (ABI 3100; Applera, Milan, Italy).
Glutathione Assay
Reduced glutathione (GSH) levels were determined in plasma andin red blood cells after trichloroacetic precipitation (28%wt/vol). GSH was determined by dithio-bis (2-nitrobenzoic acid)at 412 nm with correction with a blank reagent and using freecysteine as the standard (28).
Statistical Analyses
Simple statistical tests based on one-way ANOVA and 2 test wereused to verify differences in free SH titration and N-A transitionamong different cohorts of patients. Data are mean ±SEM.
Chemical and Structural Characterization of Plasma Albumin in FSGS
The structural approach to plasma albumin in FSGS was done originallyin seven patients, using LC-ESI-MS/MS analysis after reductionand alkylation of purified albumin (20). This approach is notreadily applicable for extensive analysis, because the sulfonicgroup at Cys 34 that is generated upon oxidation is a stableend product in the native protein but may undergo further rearrangementsduring alkylation (personal observation by G.C.). Therefore,we devised a new proteomic approach to plasma albumin that wasbased on characterization by LC-ESI-MS/MS of trypsin digestionproducts of the native protein that are more stable then thealkylated products and gave highly reproducible results. Proteomicanalysis of plasma albumin now was extended to 12 patients withFSGS, five with the idiopathic form and seven with posttransplantationrecurrence of the disease. In the first step, albumin was purifiedin nondenaturing conditions using preparative electrophoresisin native gels giving a mean recovery yield >90%. Fine structureanalysis by LC-ESI-MS/MS and determination of the exact massby ESI-MS protein analysis then was repeated in all patients.
LC-ESI-MS/MS.
The spectrum of albumin after digestion with trypsin indicatedthe presence of a parent fragment m/z 827.96 (K.ALVLIAFAQYLQQCSO3PFEDHVK.L)in the triply charged state. The m/z 827.96 compound was studiedby MS/MS showing the presence of an m/z 511.71 ion in triplecharge that was consistent with a sequence in which the Cys34 brings three additional oxygen residues, indicating oxidationof the SH to cysteic acid (+48; Figure 1). Control albumin wascharacterized by the absence of the m/z 827.96 ion in triplecharge. In Table 5 are reported the sequences with relativeXcorr and Cn of the MS/MS characterization of the m/z 827.96ion in the cohort of patients with primary nephrotic syndromeand post-transplant recurrence. Xcorr and Cn were in all caseshighly significant, confirming the presence of a cysteic groupin position 34.
Figure 1. Mass spectrometry analyses of plasma albumin in FSGS. Example of LC-ESI-MS/MS spectrum of the Cys 34 tryptic fragments of albumin from a patient with FSGS. Albumin that was purified from the patient showed, after digestion with trypsin, the parent fragments mass-to-charge ratio (m/z) 511.7 in triply charged state, indicating the formation of a cysteic residue in place of the sulfhydryl group in position 34 of albumin. Analysis of control albumin did not reveal the formation of the m/z 511.7 fragment because of lack of ionization of nonoxidized free sulfhydryl groups (SH).
Table 5. Sequence of the m/z 827.96 ion deriving from trypsin fragmentation of albumin that was purified from patients with FSGSa
ESI-MS.
Analysis of the exact mass of plasma albumin was used to confirmthe result of the structural analysis in a large cohort of patients.In all patients with FSGS, the bulk of plasma albumin presentedan exact mass of 66.555 kD, whereas this isoform was only minimallydetected in normal plasma in which the major band presents amass of 66.507 kD (data not shown).
Biomarkers of Albumin Oxidation in Patients with FSGS/IgM
On the basis of sulfonic transformation, the free SH of Cys34 of albumin should not be titrated any more and could becomea specific marker of oxidation. We devised a method for direct"in gel" determination of free Cys 34 in plasma that could beused in screening analysis. In this technique, the free Cysof albumin was targeted by maleimide-PEO2 biotin, and the reactionthen was revealed by streptavidin. This assay was extended,with the analysis of N-A transition by electrophoretic titrationcurves (24), to the whole cohort of patients. Overall, 23 patientswith primary FSGS/IgM and florid proteinuria and 14 who werepresenting posttransplantation recurrence of proteinuria werestudied. Ten patients with FSGS/IgM in stable remission andfour who received a renal transplant but were free from recurrencerepresented the negative control group for disease activity.
Cys 34 Titration.
The results are given in Figure 2, the former reporting an exampleof in gel titration in a selection of patients from each separateclinical subset as above. It is evident the lack of albuminband in the PEO2-maleimide gel in patients with proteinuria(see boxes in Figure 2). Figure 3 reports extensive resultsthat confirm a marked decrease of Cys 34 titration in all patientswith FSGS and IgM in both pre- and posttransplantation phasescompared with normal people and with MGN with some differenceswithin categories. In particular, patients with active FSGSand IgM had markedly lower levels than in the remission phase(0.43 ± 0.12 and 0.230 ± 04 versus 1.94 ±0.42 U; P < 0.003 and P < 0.001, respectively); patientswith posttransplantation recurrence showed only mildly lowerlevels than in patients with no recurrence (0.27 ± 0.04versus 0.71 ± 0.19). Normal people and other nephroticpatients with MGN had instead the same concentration (normalcontrol subjects 2.75 ± 0.33; MGN 2.48 ± 0.67).For other categories of renal diseases, see below. Overall,in patients with active FSGS/IgM, Cys 34 seems massively oxidized,whereas during the remission phase, a normal albumin pool isreconstituted.
Figure 2. Titration of the Cys 34 free SH groups of albumin in FSGS, IgM, and membranous glomerulonephritis (MGN). Titration of albumin free SH 34 by a direct "in gel" technique that uses PEO2-maleimide-biotin (top) as a specific label. According to this method, plasma proteins first are labeled with PEO2-maleimide-biotin and then are separated by monodimensional electrophoresis in nondenaturing conditions. After separation, the reaction is developed with streptavidin. Albumin from healthy people showed PEO2-maleimide staining corresponding to albumin (arrows), whereas albumin of patients with FSGS had no staining, indicating absence of a free SH that is unique in albumin at position 34 of the sequence (boxes). To prove specificity of the maleimide staining for the free SH, one sample had been treated previously with methyl-methanethiosulfonate (MMTS) that specifically blocked the free SH and prevented the maleimide binding.
Figure 3. Estimation of Cys 34-free SH group of albumin in the whole cohort of patients with FSGS, IgM, and MGN. Results are expressed as arbitrary unit of biotin per milligram of albumin. A calibration curve with several dilutions of the same plasma was prepared to obtain a confidence limit for linearity of the assay.
N-A Transition.
The rationale and the technique to define N-A transition havebeen described extensively (24). Briefly, changes in electricalcharge were determined by an electrophoretic technique thatmeasures changes in isoelectric point at any given pH from 4to 9. This technique also gives an estimate of the amount ofthe protein with a charge change that is inferred from the formationof isoform with different electrophoretic behavior. In all ofthe cases studied, the variation in electrical charge involved100% of the protein, and Figure 4A shows an example of thischange. Overall, the screening for N-A transition confirmedthe data on SH titration with some difference for patients withoutposttransplantation recurrence. In fact, N-A transition wascommon to all patients with active FSGS and IgM and to thosewith posttransplantation recurrence, whereas, in the absenceof proteinuria, in patients without posttransplantation, recurrenceand in patients with MGN, a normal electrophoretic behaviorwas reconstituted. The percentage of patients with N-A transitionin the various groups is illustrated in Figure 4C and clearlyshows a difference among categories. Table 6 reports the mean± SD of ionization parameters reproducing experimentalcurves of 10 normal control subjects and patients with proteinuria,according to the Linderström-Lang equation. Consideringthe parameters reported in Table 6, this difference can be attributedto the presence of a sulfonic group in position 34 of the sequencethat modifies our original assumption reported previously (24).
Figure 4. Electrophoretic titration curves for neutral to acid N-A transition. (A) Example of electrophoretic titration curve of a plasma sample from a patient with FSGS and for comparison of normal plasma stained with Coomassie R-250. The two proteins migrate as a single and homogeneous band throughout the pH range: Between 4 and 4.5 and between 7 and 9, they overlap, whereas in the pH range between 4.5 and 7, oxidized albumin migrates with a more acid charge. (B) Theoretical electrophoretic curve of albumin in which a cysteic group replaces a free sulfhydryl residue. According to the Linderström-Lang theory, this acid charge shift fits with the introduction of a sulfonic acid group in the molecule. Determination of albumin charge along a stable pH gradient was done according the procedure described by Bruschi et al. (24). (C) Percentage of patients with N-A transition in patients with nephrotic syndrome and different clinical activity. Presence and/or absence of fast albumin in the pH range 4.5 and 7 was evaluated in all patients that was defined in positive cases as N-A transition. Bars indicate the percentage of patients with N-A transitions in different study cohorts.
Table 6. Ionization parameters of healthy and oxidized albumin calculated according to Linderström-Lang equationa
Titration of Albumin Cys 34 in Patients with ESRF and with Other Glomerular Diseases
A few other groups of patients with different renal diseaseswere enrolled and used for demonstrating the specificity forFSGS of sulfonation of albumin Cys 34. The following groupsof patients were enrolled (Tables 3 and 4): (1) Nine patientswith chronic renal failure, two of whom were still on a conservativeregimen; (2) four children with primary MPGN; and (3) five patientswith IgA. In all cases, a normal titration of Cys 34 by PEO2-maleimidewas observed. The results presented in Figure 5 show a typicalpattern of albumin staining with the dye. It was found thatmaleimide staining, in particular, is specific for the freeSH group of Cys 34 because was abolished by preincubation ofthe protein with methyl-methanethiosulfonate at pH 5.
Figure 5. Titration of the Cys 34 free SH group of albumin by the PEO2-maleimide technique in patients with end-stage renal failure (A) and in other patients with type 1 membranoproliferative glomerulonephritis (B) or with IgA (C). The two youngest patients of the cohort with renal failure were maintained on a conservative treatment, whereas seven were treated with hemodialysis (see Table 3). Also in this case, specificity of maleimide for the free SH of Cys 34 was proved by inhibition of the binding with MMTS that is specific for this group (see sample 10 [MMTS] in A).
Albumin Gene DNA Sequence
The 14 coding exons of human albumin gene and their intro-exonjunctions were sequenced in all patients who were enrolled inthe study. In all cases, normal sequence was found, excludinga genetic basis for altered oxidation.
Susceptibility to Digestion by Trypsin
Because the antioxidation effect of albumin has been consideredfor a long time a suicidal reaction that modifies susceptibilityto digestion by common proteases, albumin was purified fromplasma of four patients with idiopathic FSGS and four with posttransplantationrecurrence and submitted to mild digestion with trypsin (seethe Materials and Methods section). The results reported inFigure 6 demonstrate the formation of fragments in the majorityof affected cases, confirming the original assumption (lanesf through n). Normal albumin was not digested following thesame conditions (lanes a through e).
Figure 6. Susceptibility to fragmentation of albumin that was purified from patients and control subjects. Albumin after purification was incubated with trypsin as indicated in the Materials and Methods section. Lanes a through e indicate albumin that was purified from normal control subjects; lanes f through i indicate albumin that was purified from patients with active FSGS; lanes j through m indicate albumin that was purified from patients with posttransplantation recurrence of proteinuria.
GSH in Plasma and in Erythrocytes
GSH levels were determined in plasma and in red blood cellsof proteinuric patients with FSGS and in control subjects. Levelswere slightly decreased in patients with active nephrotic syndromecompared with control subjects in both plasma (8.1 ±0.2 versus 8.4 ± µmol/L) and in red blood cells(6.8 ± 0.8 versus 7.5 ± 0.8 nmol/mg hemoglobin),but the difference did not reached statistical significancebecause of the low number of cases.
The underlying mechanism of antioxidant response in living systemshas been investigated widely for a long time. Several aspectsrelated to antioxidant response in human plasma remain unresolvedbecause, despite comparable or even increased exposure to oxidants,plasma levels of major intracellular antioxidant molecules suchas GSH and related enzymes are much lower than in the intracellularcompartment (0.006 versus 0.75 mM/L). Studies that used in vitromodels of oxidation convincingly indicated that plasma albuminis involved in plasma antioxidant activity by means of the uniquefree sulfhydryl groups of Cys 34 that is transformed into asulfonic group by oxidation. In vitro models also suggest thatthe intermediate of the reaction is a sulfenic (SOH-alb) thatin vivo may rapidly react with free GSH to form nonmercaptoalbumin or form dimers of the protein (29). Overall, this reactionshould involve 20 to 25% of albumin that is the amount of nonmercaptoplus dimeric albumin in plasma. Even if in vitro studies furnisha solid chemical background to a participation of albumin intothe antioxidant response in plasma, evidence that albumin oxidationtakes place in vivo has never been reported, with the exceptionof scattered reports of partial albumin oxidation in ESRF (30)and diabetes that had been obtained with indirect techniques(31,32). Studies in patients with ESRF are of particular interestbecause they show the increase of nonmercaptoalbumin that shouldrepresent the product of reaction of free plasma thiols suchas GSH and/or homocysteine with the sulfenic derivative of albumin.The quota of sulfenic albumin in patients with ESRF is estimatedto represent less than the 5% of total albumin. In this study,we demonstrate for the first time that plasma albumin in patientswith active FSGS undergoes massive and stable oxidation withchemical modification of the unique free SH of Cys 34 to a sulfonicgroup (SO3) that is an end product of the reaction. Thischange involves some relevant alterations of the protein withformation of an adduct with +48-Da molecular weight, changesof the net charge as a result of additional negative residues,and loss of free SH titration. Therefore, in vivo plasma oxidationproduces a more stable derivative than the one described inin vitro models, and, most important, SO3-alb does notdimerize but undergoes proteolysis. This later event may beconsidered a suicidal effect that results in albumin removalfrom plasma. Accordingly, many albumin fragments can be detectedin urine of patients with FSGS. As a whole, these data demonstratethat oxidation of plasma albumin occurs in vivo, and this isthe first demonstration of what seems to be a crucial physiologicprocess. Overall, the process of oxidation of albumin in FSGSseems substantially different from oxidation that is reportedin patients with ESRF because, as already discussed, it mainlyinvolves only the formation of an instable intermediate in thiscondition. According to the literature on the topic (31,32),the amount of sulfonic end product in patients with ESRF isapproximately 5% of total albumin and is under the limit ofsensitivity of the maleimide assay. Lack of observation of thispeculiar structural modification on the basis of a direct spectroscopicapproach in other cohorts of patients with primary and secondaryglomerulonephritis with and without nephrotic syndrome and inyoung adults with ESRF suggests, therefore, a good degree ofspecificity for FSGS.
This key observation leads to two considerations. The firstis that albumin, as a result of the high plasma levels, is themajor antioxidant substance in plasma and is higher than otherantioxidants. In other words, the molar level of the free SHof Cys 34 of albumin is higher than free GSH by a factor of100 (0.8 versus 0.008 mM). Second, massive oxidation of plasmaalbumin implicates new pathogenic mechanisms in FSGS relatedto oxidation. In this view, data deriving from the determinationof biomarkers of albumin oxidation (SH titration and N-A transition)suggest some clinical correlations: (1) In pretransplantationpatients, oxidation is associated with proteinuria, whereasin patients with stable remission, there is a clear trend tonormalization; (2) the effect of the nephrotic syndrome perse can be ruled out on the basis of data on patients with MGN;and (3) patients with posttransplantation recurrence also presentthe same signs of albumin oxidation that are attenuated in absenceof recurrence. Lack of complete normalization of free SH inpatients in stable relapse and in those who do not have a recurrencecould suggest presence of oxidants at lower levels, but we cannotreadily exclude that albumin in patients with FSGS/IgM havea stable reduction in antioxidation potential. This is a centralpoint because an altered response of albumin to oxidation couldrepresent a potential trigger of renal toxicity. However, albumingene sequence in patients with FSGS did not reveal any mutantsor sequence variants, ruling out the possibility of a primarydefect involving albumin structure. The finding of massive oxidationof albumin in patients with active FSGS also suggests that freeradicals are produced in excess in these patients. Several literaturedata on both human and experimental FSGS strongly support theimplication of free radicals. In fact, practically all animalmodels of nongenetic FSGS are based on free radical generation.They include puromycin and Adriamycin nephrosis in rats andMvp 17 / mice (3337). Renal infusion ofH2O2 also induces proteinuria in rats and upregulates the expressionof factors such as C/EBP homology protein (GADD 153) that alsoare upregulated in human FSGS and rat puromycin nephrosis (38).The Adriamycin model is of particular interest because the quinonestructure of the molecule allows a direct participation in redoxreaction (39,40) and may act directly as a free radical.
Few data on free radical generation during nephrotic syndromeare available in humans. However, increased oxidation for inheriteddefects that are associated with coenzyme Q deficiency as inthe case of CoQ2 mutations produces renal lesions that resembleFSGS (41). Increased peroxidation of membrane lipids and consumptionof intraerythrocyte GSH in children with FSGS also support animplication of free radicals (28,42); however, these changesare only indirect and reflect peroxidation by lipophilic substancesthat probably are not involved here. In this context, a centralpoint is the type of oxidant involved. Several studies thatinvestigated the structural effect of various oxidants on plasmaproteins in vitro (43,44) clearly indicated that oxidation ofthiol groups is specific of N-chloramine derivatives of -aminoacids. In contrast, HOCl reacts preferentially with methionineresidues and with ascorbate, and more lipophilic -chloraminesare able to cross cell membranes and oxidize intracellular componentssuch as GSH and hemoglobin. Because N-chloramines derive fromthe reaction of HOCl that is produced by phagocytes and freeamino acids, we hypothesized that phagocytes are the sourceof oxidants in FSGS. Stability and reactivity of N-chloraminesdiffer depending on their structure, but -chloramines are morestable than other similar compounds and probably propagate damagefrom the source of HOCl. Their half-life, however, is in theorder of a few minutes, and we have no chance to demonstratehigh levels of N-chloramines in plasma of patients. Analysisof sulfonation of the free Cys 34 SH may serve as a good wayto reveal their effect, and we propose a wider utilization forclinical and experimental studies.
The observation of massive oxidation of albumin in FSGS andthe possibility to have readily available laboratory assaysmay lead to preemptive therapy before the development of massiveproteinuria. Our finding also lends support to the current useof plasmapheresis for recurrence of FSGS. The success of plasmapheresisin inducing remission of proteinuria in patients with recurrentFSGS may be due to exchange of albumin (replacement of oxidizedwith normal albumin) rather than the assumed removal of a circulatingpermeability factor.
These data demonstrate massive oxidation of plasma albumin inpatients with FSGS that induces stable sulfonation of Cys 34.Oxidation of albumin is associated with disease activity andposttransplantation recurrence of proteinuria. The analyticalmethods that we have described allow rapid determination ofalbumin oxidation and may lead to prompt therapeutic intervention.
This work was conducted with the financial support of the ItalianMinistry of Health and of a grant from the Renal Child Foundation.We also acknowledge Fondazione Mara Wilma e Bianca Querci forthe financial support of the project "Nuove evoluzioni sullamultifattorialità della sindrome nefrosica."
Data were discussed critically with Prof. R. Gusmano, and weacknowledge her role. The manuscript was revised by A. Capurro.
Footnotes
Published online ahead of print. Publication date availableat www.jasn.org.
Boute N, Gribouval O, Roselli S, Benessy F, Lee H, Fuchshuber A, Dahan K, Gubler MC, Niaudet P, Antignac C: NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome.
Nat Genet 24
: 349
354, 2000[CrossRef][Medline]
Shih NY, Li J, Karpitskii V, Nguyen A, Dustin ML, Kanagawa O, Miner JH, Shaw AS: Congenital nephrotic syndrome in mice lacking CD2-associated protein.
Science 286
: 312
315, 1999[Abstract/Free Full Text]
Caridi G, Bertelli R, Carrea A, Di Duca M, Catarsi P, Artero M, Carraro M, Zennaro C, Candiano G, Musante L, Seri M, Ginevri F, Perfumo F, Ghiggeri GM: Prevalence, genetics, and clinical features of patients carrying podocin mutations in steroid-resistant nonfamilial focal segmental glomerulosclerosis.
J Am Soc Nephrol 12
: 2742
2746, 2001[Abstract/Free Full Text]
Caridi G, Bertelli R, Di Duca M, Dagnino M, Emma F, Onetti Muda A, Scolari F, Miglietti N, Mazzucco G, Murer L, Carrea A, Massella L, Rizzoni G, Perfumo F, Ghiggeri GM: Broadening the spectrum of diseases related to podocin mutations.
J Am Soc Nephrol 14
: 1278
1286, 2003[Abstract/Free Full Text]
Artero M, Biava C, Amend W, Tomlanovich S, Vincenti F: Recurrent focal glomerulosclerosis: Natural history and response to therapy.
Am J Med 92
: 375
383, 1992[CrossRef][Medline]
Savin VJ, Sharma R, Sharma M, McCarthy ET, Swan SK, Ellis E, Lovell H, Warady B, Gunwar S, Chonko AM, Artero M, Vincenti F: Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis.
N Engl J Med 334
: 878
883, 1996[Abstract/Free Full Text]
Dantal J, Bigot E, Bogers W, Testa A, Kriaa F, Jacques Y, Hurault de Ligny B, Niaudet P, Charpentier B, Soulillou JP: Effect of plasma protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome.
N Engl J Med 330
: 7
14, 1994[Abstract/Free Full Text]
DAmico G: Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome.
Semin Nephrol 24
: 179
196, 2004[CrossRef][Medline]
Koyama A, Fujisaki M, Kobayashi M, Igarashi M, Narita M: A glomerular permeability factor produced by human T cell hybridomas.
Kidney Int 40
: 453
460, 1991[Medline]
Ghiggeri GM, Artero M, Carraro M, Candiano G, Musante L, Bruschi M, Zennaro C, Ginevri F, Caridi G, Faccini L, Perfumo F, Gusmano R: Glomerular albumin permeability as an in vitro model for characterizing the mechanism of focal glomerulosclerosis and predicting post-transplant recurrence.
Pediatr Transplant 8
: 339
343, 2004[CrossRef][Medline]
Musante L, Candiano G, Bruschi M, Zennaro C, Carraro M, Artero M, Giuffrida MG, Conti A, Santucci A, Ghiggeri GM: Characterization of plasma factors that alter the permeability to albumin within isolated glomeruli.
Proteomics 2
: 197
205, 2002[CrossRef][Medline]
Reiser J, Oh J, Shirato I, Asanuma K, Hug A, Mundel TM, Honey K, Ishidoh K, Kominami E, Kreidberg JA, Tomino Y, Mundel P: Podocyte migration during nephrotic syndrome requires a coordinated interplay between cathepsin L and a3 integrin.
J Biol Chem 279
: 34827
34832, 2004[Abstract/Free Full Text]
Musante L, Bruschi M, Candiano G, Petretto A, Dimasi N, Del Boccio P, Urbani A, Rialdi G, Ghiggeri GM: Characterization of oxidation end product of plasma albumin 'in vivo.
Biochem Biophys Res Commun 349
: 668
673, 2006[CrossRef][Medline]
ISKDC: Primary nephrotic syndrome in children: Clinical significance of histopathologic variants of minimal change and of diffuse mesangial hypercellularity. A report of the International Study of Kidney Disease in Children.
Kidney Int 20
: 765
771, 1981[Medline]
Ponticelli C, Zucchelli P, Imbasciati E, Cagnoli L, Pozzi C, Passerini P, Grassi C, Limido D, Pasquali S, Volpini T, et al.: Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy.
N Engl J Med 310
: 946
950, 1984[Abstract]
Margolis J, Kenrick KG: Polyacrylamide gel electrophoresis in a continuous molecular sieve gradient.
Anal Biochem 25
: 347
362, 1968[CrossRef][Medline]
Bruschi M, Musante L, Candiano G, Santucci L, Zennaro C, Carraro M, Del Boccio P, Gusmano R, Perfumo F, Urbani A, Ghiggeri GM: Transitions of serum albumin in patients with glomerulosclerosis 'in vivo characterization by electrophoretic titration curves.
Electrophoresis 27
: 2960
2969, 2006[CrossRef][Medline]
Attanasio F, Bruschi M, Candiano G, Galletto R, Musante L, Schulein M, Rialdi G: Analytical titration curves of glycosyl hydrolase Cel45 by combined isoelectric focusing-electrophoresis.
Electrophoresis 20
: 1403
1411, 1999[CrossRef][Medline]
Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
Nature 227
: 680
685, 1970[CrossRef][Medline]
Watkins S, Madison J, Galliano M, Minchiotti L, Putnam FW: Analbuminemia: Three cases resulting from different point mutations in the albumin gene.
Proc Natl Acad Sci U S A 91
: 9417
9421, 1994[Abstract/Free Full Text]
Ginevri F, Ghiggeri GM, Candiano G, Oleggini R, Bertelli R, Piccardo MT, Perfumo F, Gusmano R: Peroxidative damage of the erythrocyte membrane in children with nephrotic syndrome.
Pediatr Nephrol 3
: 25
32, 1989[CrossRef][Medline]
Meucci E, Mordente A, Martorana GE: Metal-catalyzed oxidation of human serum albumin: Conformational and functional changes. Implications in protein aging.
J Biol Chem 266
: 4692
4699, 1991[Abstract/Free Full Text]
Himmelfarb J, McMonagle E: Albumin is the major plasma protein target of oxidant stress in uremia.
Kidney Int 60
: 358
363, 2001[CrossRef][Medline]
Suzuki E, Yasuda K, Takeda N, Sakata S, Era S, Kuwata K, Sogami M, Miura K: Increased oxidized form of human serum albumin in patients with diabetes mellitus.
Diabetes Res Clin Pract 18
: 153
158, 1992[CrossRef][Medline]
Soejima A, Matsuzawa N, Hayashi T, Kimura R, Ootsuka T, Fukuoka K, Yamada A, Nagasawa T, Era S: Alteration of redox state of human serum albumin before and after hemodialysis.
Blood Purif 22
: 525
529, 2004[CrossRef][Medline]
Ghiggeri GM, Cercignani G, Ginevri F, Bertelli R, Zetta L, Greco F, Candiano G, Trivelli A, Gusmano R: Puromycin aminonucleoside metabolism by glomeruli and glomerular epithelial cells in vitro.
Kidney Int 40
: 35
42, 1991[Medline]
Ginevri F, Gusmano R, Oleggini R, Acerbo S, Bertelli R, Perfumo F, Cercignani G, Allegrini S, DAllegri F, Ghiggeri G: Renal purine efflux and xanthine oxidase activity during experimental nephrosis in rats: Difference between puromycin aminonucleoside and adriamycin nephrosis.
Clin Sci (Lond) 78
: 283
293, 1990[Medline]
Thakur V, Walker PD, Shah SV: Evidence suggesting a role for hydroxyl radical in puromycin aminonucleoside-induced proteinuria.
Kidney Int 34
: 494
499, 1988[Medline]
OBryan T, Weiher H, Rennke HG, Kren S, Hostetter TH: Course of renal injury in the Mpv17-deficient transgenic mouse.
J Am Soc Nephrol 11
: 1067
1074, 2000[Abstract/Free Full Text]
Binder CJ, Weiher H, Exner M, Kerjaschki D: Glomerular overproduction of oxygen radicals in Mpv17 gene-inactivated mice causes podocyte foot process flattening and proteinuria: A model of steroid-resistant nephrosis sensitive to radical scavenger therapy.
Am J Pathol 154
: 1067
1075, 1999[Abstract/Free Full Text]
Bek MF, Bayer M, Muller B, Greiber S, Lang D, Schwab A, August C, Springer E, Rohrbach R, Huber TB, Benzing T, Pavenstadt H: Expression and function of C/EBP homology protein (GADD153) in podocytes.
Am J Pathol 168
: 20
32, 2006[Abstract/Free Full Text]
Doroshow JH, Locker GY, Ifrim I, Myers CE: Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine.
J Clin Invest 68
: 1053
1064, 1981[Medline]
Bertelli R, Ginevri F, Gusmano R, Ghiggeri GM: Cytotoxic effect of adriamycin and agarose-coupled adriamycin on glomerular epithelial cells: Role of free radicals.
In Vitro Cell Dev Biol 27A
: 799
804, 1991
Quinzii C, Naini A, Salviati L, Trevisson E, Navas P, Dimauro S, Hirano M: A mutation in para-hydroxybenzoate-polyprenyl transferase (COQ2) causes primary coenzyme Q10 deficiency.
Am J Hum Genet 78
: 345
349, 2006[CrossRef][Medline]
Kinra S, Rath B, Kabi BC: Indirect quantification of lipid peroxidation in steroid responsive nephrotic syndrome.
Arch Intern Med 82
: 76
78, 2000
Carr AC, Hawkins CL, Thomas SR, Stocker R, Frei B: Relative reactivities of N-chloramines and hypochlorous acid with human plasma constituents.
Free Radic Biol Med 30
: 526
536, 2001[CrossRef][Medline]
Carballal S, Radi R, Kirk MC, Barnes S, Freeman BA, Alvarez B: Sulfenic acid formation in human serum albumin by hydrogen peroxide and peroxynitrite.
Biochemistry 42
: 9906
9914, 2003[CrossRef][Medline]
Related Article
This Months Highlights
J. Am. Soc. Nephrol. 2007 18: 661-662.
[Full Text][PDF]